Sign in. It’s quick, free and it’s up to you.
An account is an optional way to support the work we do. Find out more.
Grange Castle
Pfizer cancels €400m expansion at Dublin plant
The plan was dependent on the success of a new cholesterol-reducing drug.
PFIZER HAS CANCELLED a planned €400 million expansion at its Grange Castle plant in Clondalkin, Dublin.
The pharmaceutical company didn’t formally announce the investment, but recently sought planning permission for the development of the site.
In a statement it said the proposal was dependent on the success of clinical trials of bococizumab, a cholesterol-reducing drug.
The extension would have created 350 permanent jobs and over 1,000 roles during construction.
A spokesperson for Pfizer said: “Following the decision to discontinue the development of bococizumab, part of the potential expansion for which the planning permission was sought will not now go ahead.
Expansion in relation to other incoming products will continue as planned involving investment, recruitment and new technology.
“Current and future development at Grange Castle, which is one of Pfizer’s leading biotechnology sites manufacturing a broad portfolio of biologic medicines and vaccines, is based on a number of commercialised products and pipeline compounds.”
Pfizer employs more than 3,000 people at plants in Dublin, Kildare, Cork and Sligo.
.jpg){kind=link}
have your say